Latest news with #CoreyDavis
Yahoo
20 hours ago
- Climate
- Yahoo
More Chantals in our future: Climate change will likely increase storms, flooding
Storms like Chantal, isolated flooding from sudden cloudbursts and other natural disasters will likely become more frequent and intense thanks to climate change, scientists say. 'It can be a bit tougher to be that definitive with things like heavy rainfall from tropical storms, since those are relatively rare events,' said Corey Davis, assistant state climatologist. 'But when we see new daily rainfall records of 8 inches or more in places like Chapel Hill, all from [Chantal] that was only a tropical depression, then we can at least say that this was beyond what we've seen historically from a tropical storm, and that the impacts such as heavy rain and flooding line up with what we expect due to climate change.' Heavier rainfall can be fueled by rising local and global temperatures. Increasing temperatures are a climate change indicator, and North Carolina is warmer now than in the previous century. And it is very likely the state's temperatures will rise by at least 2 to 4 degrees by the middle of this century, according to the N.C. Climate Science Report. Warmer weather leads to denser clouds that hold more water, eventually causing heavier rainfall. 'This is closely tied to another basic scientific principle — that a warmer atmosphere is also a wetter one, and weather systems like tropical storms that form in this environment can bring heavier rain over shorter time periods than we've seen historically,' Davis said Davis also commented on heavy rainfall from recent storms in North Carolina, including Hurricanes Florence and Matthew, Hurricane Helene, which had weakened before reaching Western North Carolina, and Chantal. 'The sorts of rainfall we've seen from those storms, with more than 20 inches in some cases, used to be a once-in-a-lifetime event. Now it's something we're seeing somewhere in the state every few years, or even multiple times per year like in 2024.' Weather and climate are closely related but not interchangeable. 'The climate is what we expect while the weather is what we actually get,' Davis explained. Weather describes the conditions in an area at a particular time. It's what people see on a day-to-day basis — rain, sunshine, snow, etc. Climate describes typical weather patterns in an area over a long period of time. Scientists measure weather conditions daily, then use averages to predict the climate during a particular season. Daily weather often differs from the average climate. 'For example, our climate tells us that wintertime is when we expect to get snow, but in some years we may not see any, while in other winters like this past one, we can see multiple snow events,' Davis said. Climate change is a long-term shift in average weather patterns. Differences in temperature, rainfall and greenhouse gas emissions — greenhouse gases like carbon dioxide and methane trap heat in the earth's atmosphere — are some of the markers used to measure climate change. And the scientific data demonstrates global climate change. Davis stated that greenhouse gas emissions have been the main driver of climate change. 'While the earth's atmosphere has always had some of these gases ... we've effectively supercharged the atmosphere with more of those gases than it can cycle through naturally, and that has led to the warming temperatures and its consequences,' he said. And while it might seem like a new concept, Davis said, 'it has been well known to atmospheric scientists for more than a hundred years.' Global data shows increases in carbon dioxide levels and average air temperatures dating back to the early 20th century, he said. Scientists are very confident that rising global temperatures are largely due to human actions that significantly increase carbon dioxide and other greenhouse gases in the atmosphere, according to the the most recent N.C. Climate Science Report. NC Reality Check is an N&O series holding those in power accountable and shining a light on public issues that affect the Triangle or North Carolina. Have a suggestion for a future story? Email realitycheck@
Axios
5 days ago
- Climate
- Axios
Tropical Storm Chantal highlights growing threat of quickly forming tropical weather
Tropical Storm Chantal might have had the perfect recipe for catching people unawares: It formed rapidly (only reaching tropical storm status on Saturday) over a holiday weekend and moved slowly while dropping torrential rain. Why it matters: That proved to be an especially damaging combination — breaking dams in Moore County, flooding roads, homes and businesses in Chapel Hill, killing at least one person in Chatham County and sending the Haw River to record crests. It's also one that North Carolina residents will need to watch out for more frequently. What they're saying: "The pattern and the way [Chantal] approached us ought to be setting off the alarm bells," Corey Davis, an assistant state climatologist for the State Climate Office, told Axios. With this storm and many of the most damaging ones in recent North Carolina history, he added, it's been all about excessive rain and rather than wind speeds. "And we know that with climate change and warming [oceans] storms are able to hold more moisture, and they're going to drop that moisture as heavier rainfall as it gets inland," he said. Last fall, Hurricane Helene moved quickly after making landfall but brought record rainfall. Driving the news: Davis said North Carolina is increasingly witnessing tropical storms that have the characteristics of severe thunderstorms, with small cells within the storms dropping excessive rain in some places but not others. On Sunday, just a few miles could make a few difference, with parts of Orange County seeing more than seven inches of rain in a 12-hour period, while parts of Durham, only a short drive away, got two to three inches. In that way, the storm was similar to last year's Potential Tropical Cyclone 8, which dropped 20 inches on Carolina Beach, and Tropical Storm Debby, which dumped large amounts of rain across parts of southeastern North Carolina. The latest: Thousands of customers were still without power as of Monday afternoon, according to Duke Energy. Crews on Monday were still searching for two kayakers who went missing on Jordan Lake Sunday. Over 100 roads were closed across North Carolina due to Chantal, WRAL reported. Between the lines: It's shaping up to be an especially busy hurricane season in the Atlantic, with Chantal becoming the third named storm. NOAA is forecasting an above-normal season, with 13-19 named storms predicted, Axios previously reported. "This is really pretty early in the season to get our third named storm," Davis said. "We're still over two months away from the peak of the season, so I think what this tells us is there's more where this came from."
Associated Press
26-06-2025
- Business
- Associated Press
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are: US-based Investors: 1-877-407-0752 International Investors: 1-201-389-0912 Conference Call ID: 13754335 The webcast link for the event can be found here: A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event. About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to J&J Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors +1 212 915 2577 [email protected] Media Contact Virginia Amann, Founder/CEO ENTENTE Network of Companies +1 833 500 0061 ext 1 [email protected] SOURCE: Protagonist Therapeutics press release
Business Wire
25-06-2025
- Health
- Business Wire
DaysToHappy Unveils Happy 2.0: Scalable Mental Health Support for the Modern Workplace and Campus
BOISE, Idaho--(BUSINESS WIRE)--DaysToHappy today announced the launch of Happy 2.0, a revolutionary mental health platform designed to help HR leaders and university administrators address rising rates of depression and anxiety among employees and students—at scale, and without overburdening traditional mental health systems. 'We're all about results—improving mental health by twenty percent in three weeks.' Built for today's fast-moving organizations and campuses, Happy 2.0 combines AI-driven mental health training, live group coaching, support communities, and ongoing assessments to provide immediate, around-the-clock mental health support—without the delays or limitations of therapist availability. 'We've built Happy 2.0 to solve what HR and campus wellness leaders have struggled with for years—how to deliver meaningful, measurable mental health support to thousands, instantly,' said Corey Davis, Founder of DaysToHappy. 'We're all about results—improving mental health by twenty percent in three weeks.' Key Benefits for HR and University Leaders: No App. No Login. No Integration Required. Launch to thousands of users in seconds, with zero tech lift. Available 24/7 Always-on access to coaching and community support, beyond office or counseling center hours. Scales with Your Organization Whether you're supporting 500 employees or 40,000 students, Happy 2.0 adapts instantly to meet demand. Drives Measurable Behavior Change Built-in assessments and tracking help HR and wellness teams see improvements over time, from engagement to emotional resilience. 'We all grew up with PE—Physical Education. But the world has changed. Now is the time for ME—Mental Education,' said Corey Davis. 'Happy 2.0 empowers organizations and institutions to support mental well-being proactively and at scale.' Why It Matters Now Traditional mental health solutions rely on therapists whose availability is limited—and often inaccessible during key moments of stress. Happy 2.0 changes the model, offering instant, scalable support that complements (not replaces) clinical care by meeting users where they are, when they need it. Whether you're leading a workforce or a student body, Happy 2.0 makes it possible to provide whole-person support that's always on, always human, and always impactful. About DaysToHappy, Inc. DaysToHappy is a behavior technology company transforming the way people experience mental health support. Through innovative tools that blend AI, interactive learning, live coaching, and community, DaysToHappy improves emotional well-being without the constraints of therapy-based systems.
Yahoo
24-06-2025
- Business
- Yahoo
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, June 24, 2025 at 8:15am ET / 5:15am PT. The data will be provided in a morning press release and presented during the webcast. Details on how to access the live webcast of the call will be available in the morning press release and on the Nektar website at A replay of the webcast will be available for at least 30 days following the event. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit and follow us on LinkedIn. For Investors: Corey Davis, PhDLifeSci Advisors212-915-2577cdavis@ For Media: Madelin HawtinLifeSci Communications603-714-2638mhawtin@ View original content to download multimedia: SOURCE Nektar Therapeutics
